智通财经APP获悉，华夏创新药(03525)涨超2%，截至发稿，涨2%，报10.2港元，成交额49.13万港元。
据悉，华夏创新药于9月29日正式在港交所上市，该基金由华夏基金（香港）与富兰克林邓普顿合作开发，全称为华夏富兰克林富时创新药ETF，其追踪富时ETF通创新药指数，指数包含30只符合港股通资格的中国香港上市证券及70只发达市场证券，中国香港市场与其他发达市场目标权重分别为65%、35%。
开源证券指出，在全球MNC持续补充创新管线、中国创新药研发效率与成本优势逐步显现的背景下，创新药出海有望由单点BD交易向常态化、平台化合作演进，具备全球竞争力管线、差异化技术平台及持续BD能力的创新药企有望迎来价值重估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.